Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Prostate Cancer & BPHArchives

Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?
Prostate Cancer & BPH
 1 min.

 Published on 12/06/2026 |  Original article (Full-text)  | Zhe Chen et al. | Journal of Radiation Research. Volume 67(2).

The use of hypofractionated radiotherapy (HFRT) after prostatectomy has expanded because of its radiobiological advantages and its potential to reduce treatment burden. Stereotactic body radiotherapy (SBRT), an even more condensed treatment approach, has recently emerged as a possible salvage option...

HTML version PDF version  Print abstract

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Prostate Cancer & BPH
 1 min.

 Published on 05/06/2026 |  Original article (Full-text)  | Neal D. Shore et al. | Future Oncology 2026; 22(12): 1397-1408

Phase I investigation of the enhancer of zeste homolog 2 inhibitor, mevrometostat, plus enzalutamide showed promising antitumor activity versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03460977). MEVPRO-1 (open label) and MEVPRO-2 (double blind)...

HTML version PDF version  Print abstract

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making
Prostate Cancer & BPH
 1 min.

 Published on 29/05/2026 |  Original article (Full-text)  | Lilia Bardoscia et al. | Expert Review of Clinical Pharmacology 2026; aop:10.1080/17512433.2026.2677891

Prostate cancer is well known to be androgen-dependent, with growth directly relying on the androgen receptor signaling pathway. In fact, androgen deprivation therapy, with or without Docetaxel and/or newer hormonal drugs such as Abiraterone acetate, Enzalutamide, Apalutamide, and Darolutamide, remains...

HTML version PDF version  Print abstract

Fusion genes in precision oncology: prostate cancer as a diagnostic case study
Prostate Cancer & BPH
 1 min.

 Published on 22/05/2026 |  Original article (Full-text)  | Rebecca A. Morgan et al. | Expert Review of Molecular Diagnostics 2026; 26(5): 379-393

Fusion genes represent one of the most specific molecular alterations in human cancer and have long served as important diagnostic and therapeutic biomarkers. Advances in next-generation sequencing have driven a rapid expansion in fusion gene discovery. Clinical translation has lagged however, particularly...

HTML version PDF version  Print abstract

Drinking water nitrate, disinfection byproducts, and prostate cancer incidence in the Agricultural Health Study
Prostate Cancer & BPH
 1 min.

 Published on 15/05/2026 |  Original article (Full-text)  | Maya Spaur et al. | Journal of the National Cancer Institute. Volume 118(4).

Drinking water can be an important source of exposure to nitrate and disinfection by-products, including trihalomethanes (THMs) and haloacetic acids (HAAs). N-nitroso compounds formed endogenously after nitrate ingestion are animal carcinogens, and THM and HAA exposures increase the risk of some cancers....

HTML version PDF version  Print abstract